PharMolix, a Tsinghua-affiliated AI startup, was founded in June 2023, originating from the Institute for AI Industry Research (AIR) at Tsinghua University, established by Academician Zhang Yaqin. Professor Guo Qiang from Tsinghua University and Chief Researcher Professor Nie Zaiqing from AIR serve as the company's Chief Scientists. The company focuses on building foundational large models for the biomedical industry and has launched ChatDD, a new generation conversational drug development assistant.

In 2023, at the China Academy of Information and Communications Technology (CAICT) summit on large model-driven new digital economy ecosystems, PharMolix's "ChatDD" was selected as the only biomedical large model application case and was included in the first "2023 Large Model Application Case Collection". Additionally, the company received the "ScienceAI Top 10 Leading Enterprises" title, making it the youngest company selected among the top ten national scientific intelligence enterprises. Since its establishment over a year ago, PharMolix has published 5 innovative AI papers in the biomedical field at top international machine learning conferences including NeurIPS, ICML, and KDD. The company has deep collaborations with pharmaceutical companies such as Fosun Pharma and BioOcean, transforming cutting-edge research achievements of multimodal biomedical large models into applications, driving the intelligent development of the pharmaceutical industry.

Currently, PharMolix has established strategic partnerships with more than ten leading biomedical enterprises and institutions. Meanwhile, technologies such as the biomedical large model BioMedGPT, developed in collaboration with Tsinghua University as open source, have been widely applied in industry research work.